Combination Products: One plus one, two or three, equals one
When an application for a drug, biologic or device enters the FDA it’s triaged to the appropriate area for review. What happens if the potential product is a combination of the two, or all three -- in steps the Office of Combination Products (OCP).
- Serving as a focal point for combination product issues for agency reviewers and industry.
- Developing guidance and regulations to clarify the regulation of combination products.
- Assigning an FDA center to have primary jurisdiction for review of both combination and single entity (i.e., non-combination) products where the jurisdiction is unclear or in dispute.
- Ensuring timely and effective premarket review of combination products by overseeing the timeliness of and coordinating reviews involving more than one agency center.
- Ensuring consistency and appropriateness of post market regulation of combination products.
- Resolving disputes regarding the timeliness of premarket review of combination products.
- Updating agreements, guidance documents, or practices specific to the assignment of combination products.